Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06263322
Other study ID # IRB202200419
Secondary ID R21AG073769
Status Recruiting
Phase N/A
First received
Last updated
Start date November 16, 2023
Est. completion date October 17, 2026

Study information

Verified date February 2024
Source University of Florida
Contact Institute_on_Aging
Phone 352-273-5919
Email recruit@aging.ufl.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In recent years, mobile health (mHealth) apps have promised improved monitoring of health conditions to improve clinical outcomes. The objective of this study is to conduct a pilot randomized clinical trial (RCT) to evaluate the impact of using remotely collected patient generated health data (PGHD) from older patients undergoing bypass surgery due to chronic limb threatening ischemia. The hypothesis is that integrating PGHD with an EHR system will help providers manage post-surgical symptoms and thus improve post-operative mobility and quality of life health outcomes.


Description:

This pilot study aims to evaluate the feasibility of collecting patient generated health data (PGHD) remotely for aiding care management of patients with chronic limb threatening ischemia following vascular bypass or revascularization. DRemote data collected from a publicly available smartwatch will be displayed on an EHR interface for providers to view PGHD. The test of feasibility entails multiple components that include implementing a provider interface for viewing and acting on PGHD, establishing safety, ensuring quality assurance (e.g. quality of remote data collection), successful recruitment and retention of participants, and sufficient remote response rates from patients. This is a single-masked RCT pilot study design. The work leverages our existing mobile health platform called Real-Time and Online Assessment and Mobility Monitor (ROAMM) to integrate ecological PGHD with the UF Epic® EHR system. We will randomize 50 older adults (>=60 yrs) to either ROAMM-EHR or an active comparison group. Importantly, both groups will receive smartwatches with the ROAMM app. This removes the potential influence that interacting with a smartwatch and reporting symptoms may have patient behaviors and post-surgical outcomes. However, only data from the ROAMM-EHR group will be seen by physician teams; data from the active comparison group will be stored but not displayed. All participants will be prompted multiple times per day to report their symptoms (see table 2 for description), wound healing and any complications. Smartwatch sensors will capture information about activity levels and community mobility via the location services (GPS). Provider teams will be trained to use the EPIC interface that displays data from the ROAMM app under the Technology Acceptance Model. They will be asked to do regular checks to monitor patient's symptoms, complications and activity patterns. Participants: We will enroll 50 older adult patients (age >=60 years) scheduled for vascular bypass or revascularization. Patients will be randomized (stratified by gender) across comparison groups. Eligibility criteria are as follows. Inclusion criteria: age >= 60; Patients with chronic limb threatening ischemia who are undergoing re-vascular surgery [endovascular or open re-vascularization (bypass)]. Exclusion criteria: High risk of post-surgical amputation based on study physician judgement, non-english speaker, diagnosis of an age-related dementia (e.g. Alzheimer's Disease); unable to communicate because of severe hearing loss; uncorrectable vision impairment that compromises clinical assessments or would cause a safety concern, other significant co-morbid disease that in the opinion of the investigators and study physician would impair the ability to participate in the study or be a safety concern; We will evaluate whether ROAMM-EHR information impacts traditional clinically relevant measures of lower extremity function and overall quality of life. We will measure the change in 6-min walk distance at post-surgery (window: 30-50 days) versus pre-surgery. For the self-reported quality of life, we chose the Medical Outcomes Study 36-Item Short Form (SF-36) and modified Brief Pain Inventory. We propose a total sample size of 50 participants - 2 randomized groups of 25. In pilot studies, the goal is to have a sample size for estimating the margin of error that is sufficiently small for planning future trials. With a conservative 10% loss to follow-up, the margin of error in a 90% confidence interval will not exceed 12% of the point estimate in the SF-36 physical composite score (1.88 points) or 6-min walk distance (22.9 meters). Thus, all confidence interval widths are sufficiently small to plan future studies.


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date October 17, 2026
Est. primary completion date October 17, 2026
Accepts healthy volunteers No
Gender All
Age group 60 Years to 100 Years
Eligibility Inclusion Criteria: - age >= 60; Patients with chronic limb threatening ischemia who are undergoing re-vascular surgery [endovascular or open re-vascularization (bypass)]. Exclusion Criteria: - High risk of post-surgical amputation based on study physician judgement, non-english speaker, diagnosis of an age-related dementia (e.g. Alzheimer's Disease); unable to communicate because of severe hearing loss; uncorrectable vision impairment that compromises clinical assessments or would cause a safety concern, other significant co-morbid disease that in the opinion of the investigators and study physician would impair the ability to participate in the study or be a safety concern

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Actionable remotely generated health data
Remotely captured, patient generated health data will be used to inform provider care following re-vascular surgery in patients with chronic limb threatening ischemia
Non-Actionable remotely generated health data
Remotely captured, patient generated health data is captured, but will not be used to inform provider care following re-vascular surgery in patients with chronic limb threatening ischemia

Locations

Country Name City State
United States Institute of Aging Gainesville Florida

Sponsors (2)

Lead Sponsor Collaborator
University of Florida National Institute on Aging (NIA)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary 6-min walk distance Patients are asked to complete as much distance as possible over a standardized course Before and approximately 30 days post-surgery
Secondary self-reported quality of life Outcome will be assessed as the summary score on the Medical Outcomes Study 36-Item Short Form (SF-36) Before and approximately 30 days post-surgery
See also
  Status Clinical Trial Phase
Recruiting NCT06032065 - Sequential Multiple Assessment Randomized Trial of Exercise for PAD: SMART Exercise for PAD (SMART PAD) Phase 3
Active, not recruiting NCT03987061 - MOTIV Bioresorbable Scaffold in BTK Artery Disease N/A
Recruiting NCT03506633 - Impacts of Mitochondrial-targeted Antioxidant on Peripheral Artery Disease Patients N/A
Active, not recruiting NCT03506646 - Dietary Nitrate Supplementation and Thermoregulation N/A
Active, not recruiting NCT04677725 - NEtwork to Control ATherothrombosis (NEAT Registry)
Recruiting NCT05961943 - RESPONSE-2-PAD to Reduce Sedentary Time in Peripheral Arterial Disease Patients N/A
Recruiting NCT06047002 - Personalised Antiplatelet Therapy for Patients With Symptomatic Peripheral Arterial Disease
Completed NCT03185052 - Feasibility of Outpatient Care After Manual Compression in Patients Treated for Peripheral Arterial Disease by Endovascular Technique With 5F Sheath Femoral Approach N/A
Recruiting NCT05992896 - A Study of Loco-Regional Liposomal Bupivacaine Injection Phase 4
Completed NCT04635501 - AbsorbaSeal (ABS 5.6.7) Vascular Closure Device Trial N/A
Recruiting NCT04584632 - The Efemoral Vascular Scaffold System (EVSS) for the Treatment of Patients With Symptomatic Peripheral Vascular Disease From Stenosis or Occlusion of the Femoropopliteal Artery N/A
Withdrawn NCT03994185 - The Merit WRAPSODY™ Endovascular Stent Graft for Treatment of Iliac Artery Occlusive Disease N/A
Withdrawn NCT03538392 - Serranator® Alto Post Market Clinical Follow Up (PMCF) Study
Recruiting NCT02915796 - Autologous CD133(+) Cells as an Adjuvant to Below the Knee Percutaneous Transluminal Angioplasty Phase 1
Active, not recruiting NCT02900924 - Observational Study to Evaluate the BioMimics 3D Stent System: MIMICS-3D
Completed NCT02901847 - To Evaluate the Introduction of a Public Health Approach to Peripheral Arterial Disease (PAD) Using National Centre for Sport and Exercise Medicine Facilities. N/A
Not yet recruiting NCT02455726 - Magnesium Oral Supplementation to Reduce Pain Inpatients With Severe Peripheral Arterial Occlusive Disease N/A
Not yet recruiting NCT02387450 - Reduced Cardiovascular Morbi-mortality by Sildenafil in Patients With Arterial Claudication Phase 2/Phase 3
Withdrawn NCT02126540 - Trial of Pantheris System, an Atherectomy Device That Provides Imaging While Removing Plaque in Lower Extremity Arteries N/A
Completed NCT02022423 - Physical Activity Daily - An Internet-Based Walking Program for Patients With Peripheral Arterial Disease N/A